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Summary  
Microcephaly is an important sign of neurological malformation and predictor of future disability. 
The recent outbreak of Zika virus and congenital Zika infection has brought the world’s attention 
to the links between infection and microcephaly. However, Zika virus is only one of the 
infectious causes of microcephaly and, though the contexts in which they occur vary greatly, all 
are of concern. In this review, we summarise important aspects of the major congenital infections 
that can cause microcephaly, describing the epidemiology, transmission, clinical features, 
pathogenesis and long-term consequences. We include the infections that cause substantial 
impairment: cytomegalovirus, herpes simplex virus, rubella virus, Toxoplasma gondii, and Zika 
virus. We highlight potential issues with the classification of microcephaly and show how some 
infants affected by congenital infection may be missed or incorrectly diagnosed. While the 
world’s current focus on Zika virus is remarkable, preventing all infectious causes of 
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microcephaly and appropriately managing its consequences remain important global public health 
priorities.  
 
Introduction  
This review was conducted in response to the recent outbreak of microcephaly associated with congenital 
Zika virus (ZIKV) infection, first identified in Latin America. Attention has been drawn to ZIKV because 
the previously unknown congenital syndrome was discovered in a susceptible population and can 
potentially affect a very large number of infants. ZIKV however is one of a group of infectious diseases 
that can be transmitted to the fetus and cause microcephaly and the microcephaly is likely to represent the 
tip of the iceberg in terms of developmental abnormalities, forming part of a syndrome for each infection. 
Understanding the different causes of microcephaly will help clinicians, researchers, and hopefully policy 
makers contextualize the recent outbreak and can be applied to help the individual child, as well as to 
inform appropriate planning of services for the population.  
In this article, we review the major congenital infections that can cause microcephaly, focusing 
on those with the largest disease burden and the strongest evidence for causation: 
cytomegalovirus (CMV), herpes simplex virus (HSV), rubella virus, Toxoplasma gondii (T. 
gondii), and ZIKV. We describe the epidemiology, pathogenesis, transmission, clinical features 
and long-term disability in childhood. Less frequent causes of primary microcephaly are not 
considered here. While congenital syphilis has a high disease burden in regions affected by ZIKV 
and varicella virus has recognised neurotropic properties, published reports describing primary 
microcephaly in the context of these two infections are scarce. 
 
Microcephaly 
Microcephaly is a clinical diagnosis made at or after birth that describes a small head. It does not 
necessarily mean abnormal brain development and some children with microcephaly are healthy. 
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An accepted definition of microcephaly is occipito-frontal head circumference (OFC)>2 standard 
deviations below the median (<-2 z-scores), for gestational age and sex in an appropriate healthy 
reference population, with severe microcephaly defined as <-3 z-scores.1-3 The reference range 
and population from which a definition is taken can vary, for example country-specific ranges, 
the World Health Organization (WHO) child-growth ranges for term infants, the Fenton ranges 
for preterm infants, and the InterGrowth reference ranges are all used.4 This limits the 
comparability of microcephaly prevalence estimates and accounts for a proportion of the global 
variability in rates. The WHO currently recommends the Intergrowth-21 criteria if the gestational 
age is known and the WHO Child Growth Standards if it is not.1,5,6 In addition, and probably 
more importantly, inconsistency in frequency and rigour of measurement, and completeness of 
reporting, makes population prevalences difficult to ascertain. A recent study across Europe 
found a prevalence, excluding genetic conditions, of 1·53 (95% CI 1·16, 1·96) per 10,000 
“births” (including live births, fetal deaths from 20 weeks gestation and termination of pregnancy 
for fetal anomaly). Including genetic conditions would increase the prevalence to approximately 
2·0 per 10,000. There was considerable variation in the estimates from 0·41/10,000 in Portugal to 
4·25/10,000 in UK and in the definition of microcephaly (<-2 z-scores, <-3 z-scores and clinical 
decisions), the reference ranges used and methods of ascertainment.7  
Microcephaly can be divided into primary- i.e. develops before 32 weeks’ gestation8 or birth9- 
and secondary- i.e. microcephaly that develops after this time. Primary microcephaly, the focus of 
this review, is generally due to disturbed neurogenesis (mitosis or progenitor cell function) or 
death of neuronal progenitors.9,10 Secondary microcephaly normally relates to the postnatal 
development and maturation of neurons (dendritic processes and synaptic connections).8 Infection 
can lead to both primary or secondary microcephaly but this differentiation is often not possible if 
the appropriate head circumference measurements are not taken. In high-income countries, 
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microcephaly is predominantly due to non-infectious causes,11,12 including genetic abnormalities, 
nutritional deficiencies, hypothyroidism, brain injury, alcohol, drugs, and placental 
insufficiency.8,9 A multi-centre retrospective analysis from Germany found that only 25 of 403 
(6·2%) cases of microcephaly (for which a cause was identified) were due to maternal infections 
in pregnancy.12 The prevalence of in utero or perinatal infections in cases of severe microcephaly 
is higher e.g. 46 of 284 (16%) cases in New York 2013-15.13 
A reduction in head size may be associated with intrauterine growth restriction, for example with 
CMV and ZIKV. This can be either symmetrically or asymmetrically reduced in size in relation 
to the overall anthropometry of the infant. The gestation at which an insult occurs, will determine 
when microcephaly is clinically detectable. An infection close to birth may result in brain damage 
but with a normal head circumference. Recent data suggest that microcephaly may be poorly 
sensitive for screening infants severely affected by congenital ZIKV infection, particularly as this 
consists of many other manifestations.14 Clinically apparent, microcephaly is one of many fetal 
brain abnormalities that can lead to later neurodevelopmental sequelae.15 Although a clinical 
diagnosis of microcephaly with normal brain imaging does not necessarily mean impaired brain 
growth, a reduction in skull volume is indicative of underlying cerebral cortical volume loss.8,16 A 
study of Finnish infants admitted to a neonatal ward for example, showed that a one standard 
deviation increase in head circumference at birth was associated with a 0·8-1·5 unit increase in 
cognitive scores at 56 months.17  
If we use microcephaly to screen for congenital diseases, and if OFC is normally distributed in 
the reference population, 2·3% of the population will be classified as having microcephaly, many 
of whom will be healthy. Conversely, many neonates with congenital infections that affect the 
brain will not have severe enough manifestations to cause microcephaly. To illustrate this, we 
simulate two scenarios (Figure 1). A definition of <-3 z-scores (0·1% of the population)18,19 is 
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expected to be 99·9% specific, although much less sensitive (57%).4 An assessment of 1501 cases 
of suspected microcephaly reported to the Brazilian notification system, showed that 21·7% of 
notified cases classified as ‘definite or probable’ had a normal head circumference (>-2 z-scores) 
and this cut-off had a sensitivity of 83% and specificity of 98%.14 So although microcephaly is a 
good screening diagnosis for brain damage caused by a congenital infection, some cases will be 
normal and cases with neurological damage may not be identified. Further tools must therefore be 
employed.  
 
Pathogenesis and embryology 
The central nervous system becomes established from day 22 of embryonic development when 
the neural tube is formed.20 The embryonic brain is initially composed entirely of proliferative 
neuronal progenitors which reside within the ventricular zone (VZ) bordering the neural tube 
lumen. However, with subsequent development, neurons begin to emerge and a new population 
of deeper subventricular zone (SVZ) neural progenitors arises. Proliferation of the SVZ cells 
contributes to further expansion of the brain’s neuronal population. Proliferative VZ and SVZ 
neuronal progenitors persist until around mid-gestation, providing a target for pathogens via the 
cerebral blood supply which is now fully established. Experimental evidence shows that 
regulation of neural progenitor numbers and sub-types is vital for controlling brain size and 
morphology (Figure 2). For example, mouse studies reveal that abnormal expansion of the VZ or 
SVZ neural progenitors increases brain size and produces macrocephaly.21,22 In contrast, a 
reduction in neural progenitor numbers due to cell death, cell cycle arrest or premature neuronal 
differentiation reduces brain size and produces microcephaly.23-26 
 
The pathogenesis of CMV, HSV, rubella and ZIKV is described below. Little information is 
 6 
available on the mechanisms of congenital brain infection for T. gondii, where additional research 
is needed. The congenital infections we describe in this paper (summarised in Table 1) are 
responsible for a range of developmental brain defects, with the more severe cases occurring after 
infection during the first trimester of gestation, when the neural progenitors are actively 
multiplying and producing neurons (Figure 2).27-36Analysis of material from aborted human 
fetuses confirms that brain cells are susceptible to viral infection (ZIKV,30 CMV,37 HSV35,38 and 
rubella39). Moreover, human cell culture systems demonstrate that neural progenitors are targeted 
by these pathogens (ZIKV brain organoids40,41; HSV iPS-derived cell culture42; ZIKV 
neurospheres 43; CMV neural precursors37). This research suggests that perturbation of neural 
progenitor populations may be the main cause of infection-related microcephaly.  
 
CMV 
CMV is capable of altering progenitor and neuronal fates through the downregulation of 
multipotency markers including Sox2 and Nestin.44,45 Neuronal differentiation has been found to 
be inhibited or delayed by CMV37,46,47 or to occur prematurely after infection.44 Recently, a new 
molecular mechanism downstream of CMV brain infection has emerged: PPARγ (peroxisome 
proliferator-activated receptor gamma) was found to increase following CMV infection of human 
neural stem cells and human fetal brain sections. Activation of PPARγ function alone was 
sufficient to impair neuronal differentiation, and a PPARγ inhibitor restored normal 
differentiation. Moreover, nuclear PPARγ was detected in the brains of congenitally infected 
fetuses.47 These findings support a role for PPARγ in mediating congenital CMV brain disease. 
 
HSV 
HSV can infect multiple brain cell types (human35,38, in vitro 42 and mouse48) but how this leads 
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to microcephaly is unclear. Infected organs including the brain, show tissue necrosis post-
mortem.36 In vitro and animal studies suggest that HSV may initially induce an immune response 
that stimulates neural stem cell proliferation. Subsequently, brain infiltration by CD8(+) T cells 
limits proliferation through the stimulation of interferon-gamma.49 Operation of a similar 
immune-mediated mechanism following congenital brain infection leading to microcephaly is 
possible but remains to be verified. 
 
Rubella 
The mechanisms by which rubella virus induces microcephaly remain largely unknown. Most 
human embryonic tissues can be infected by rubella virus39,50 and brain vessels have been found 
to degenerate following rubella infection.50-52 This suggests that a neurodegenerative mechanism 
could be a potential underlying cause of rubella-induced microcephaly in humans. There is also 
indirect evidence that rubella infection can slow the rate of cell division although this has not 
been confirmed in human neural cells in culture.28  
 
ZIKV 
Congenital viral infections and brain development studies have benefited from recent advances in 
the growth of human cells in 3-dimensional (3D) culture. Cell aggregates called ‘neurospheres’ 
are formed initially but with continued culture they can form ‘organoids’ that mimic some 
features of true organs. Studies employing these techniques have confirmed that neural 
progenitors (ventricular zone (VZ) and later subventricular zone (SVZ)) are indeed the 
commonest brain cell type infected by ZIKV (brain organoids40,41 and neurospheres43). The 
exposure of these 3D cell cultures to the virus mimics many features of microcephaly in humans, 
including a decrease in neuronal production, reduced VZ thickness and overall smaller 
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organoids.40,41,53 This reduction in growth seems to result from cell cycle arrest54 and/or an 
increase in cell death,41,43,53,54 and could indeed explain the microcephaly phenotype observed in 
ZIKV-infected human fetuses. Entry of ZIKV into neural progenitors has been suggested to occur 
via viral receptor AXL, which mediates ZIKV and dengue virus entry into human skin cells,55 
and  is strongly expressed in VZ and SVZ neural progenitors.56,57 However, a recent study using 
human brain organoids revealed that genetic ablation of AXL alone is unable to prevent ZIKV 
infection, suggesting that other cell adhesion or entry factors may be involved.58 Human fetal 
organotypic slice culture studies reveal that phospho-TANK Binding Kinase 1 (pTKB1), 
relocates from centrosomes to mitochondria following ZIKV infection producing mitotic defects 
and supernumerary centrosomes that may exacerbate cell death.57,59 Injection of ZIKV into 
pregnant macaques and mice, or into the mouse brain, has recently confirmed some of the 
observations from human in vitro culture systems.60-62 Dang and colleagues also discovered that 
ZIKV infection activates TLR3 (involved in activation of an immune response) and that TLR3 
inhibition can attenuate apoptosis and decrease growth induced by viral infection.40 The 
comparison of transcriptome profiles derived from infected and non-infected animal tissue also 
highlights new potential molecular viral targets. These include the down-regulated expression of 
an extensive list of genes (all centrosome-related) previously associated with autosomal recessive 
primary microcephaly (ASPM, CENPF, MCPH1, STIL, Cep135).60,61 This suggests that the 
underlying pathogenesis of autosomal recessive and virally induced microcephalies may be 
similar, although this is yet to be confirmed. 
 
Infection in pregnancy: Epidemiology, transmission and clinical features  
Table 1 describes the epidemiology and clinical features of the main infections associated with 
microcephaly in pregnant women/adults.  
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CMV 
Most women of childbearing age in low- and middle-income country (LMICs) have long-lasting 
immunity from prior CMV infection but viral reactivation can take place in pregnancy or during 
periods of immunosuppression. In Sub-Saharan Africa, Latin America and South Asia, over 90% 
of the general population have IgG antibodies compared to a seroprevalence of 40-60% in high-
income countries.63-68 Prevalence of congenital CMV infection in high-income countries is 
estimated to be  0·7% of all live births, or 1-5% in low-income countries.63,66,69 
The risk of in utero transmission varies according to whether maternal CMV infection is primary, 
a reactivation of latent infection, or superinfection with another CMV strain.63 Primary infection 
has the highest risk of in-utero transmission and fetal disease is more severe, particularly when it 
occurs earlier in pregnancy. Overall, most cases of congenital CMV infection result from non-
primary maternal infection but most of these are asymptomatic.70 The risk of transmission 
increases with advancing gestational age, with 35% of mothers who have a primary infection in 
the first trimester giving birth to infected newborns, compared to 65% who are infected in the 
third trimester.71 Rates of transmission in non-primary infection are less certain but are generally 
reported to be lower.63,72,73 The risk of congenital CMV infection is increased by maternal HIV 
infection both for HIV exposed uninfected and HIV infected infants.63 In-utero HIV transmission 
has been shown to be particularly associated with congenital CMV.74 
  
 
HSV 
Primary microcephaly is a relatively rare complication of perinatal HSV infection and is mainly 
found in association with in-utero infection which accounts for only 5% of cases.75 Global 
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average seroprevalence is 18% amongst women of childbearing age but this includes huge 
variations: from 4·1% in Japan to 62% in East Asia and 70% in Sub-Saharan Africa.76,77 Neonatal 
infection at the time of birth from mothers with symptomatic genital infection is more common 
but does not cause primary microcephaly.  
 
Rubella 
Rubella is a vaccine-preventable disease and rates of infection are largely dependent on the 
coverage of immunisation programmes. The global incidence of congenital rubella syndrome has 
reduced from 0·1-0·2 per 1000 live births prior to vaccination to near elimination (<0·01 per 
100,000 live births) in areas with comprehensive vaccination rates.78 Vaccination programmes 
were widespread in most countries in 2014 except in Sub-Saharan Africa and South Asia.79 
Despite widespread vaccination programmes an estimated 9.4% of pregnant women remain 
seronegative worldwide and therefore susceptible to infection.80 In areas without vaccination 
programmes, incidence of congenital rubella syndrome has been estimated at 19-283 per 100,000 
live births in the African region and 18-309 per 100,000 live births in the South Asian region.78  
 
T. gondii  
Most women of childbearing age in Latin America (51-72%), Central Europe (58%), and West 
Africa (54-77%) have specific IgG antibodies to T. gondii.81 Conversely, relatively few women of 
childbearing age are found to be seropositive in South-east Asia, China and Korea (4-39%), 
Scandinavia (11-28%), and the United States (15%).81,82 Mother-to-child transmission 
predominantly occurs following primary infection during pregnancy. The global incidence of 
congenital toxoplasmosis is estimated at 1·5 cases per 1000 live births (95% credible interval 1·4, 
1·6), being highest in some Latin America countries (average, 3·4 per 1000) and lowest in parts 
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of Europe (0·5 per 1000).83 The risk of congenital infection may rise due to reactivation of T. 
gondii from immunosuppression, for example resulting from HIV.84  
 
ZIKV 
ZIKV has been described for over 60 years with intermittent case reports until outbreaks in Yap 
Island (estimated 73% (95% CI 68, 77) of population infected) in 2007, French Polynesia (up to 
66% IgG +ve) in 2013 and Brazil in 2015.55,85,86 It is currently documented in 84 countries or 
subregional areas and 31 have reported microcephaly or neurological malformations associated 
with ZIKV.87 The prevalence of suspected disease in women of childbearing age is 5400 per 
100,000 in Brazil.88  
 
Laboratory diagnosis during pregnancy  
Any pregnant woman presenting with fever and/or rash should be evaluated for risk of infections 
that are potentially transmitted to the fetus. There are many infectious causes of rash, for example 
Parvovirus B19, measles and varicella zoster, and extensive guidelines exist describing when 
testing should be done.89  
During the acute infection, laboratory confirmation is usually only possible where clinical 
symptoms are present in the mother. Primary CMV, HSV, T. gondii, and ZIKV infections may be 
asymptomatic and therefore the opportunity to confirm acute infection can be missed.90 In acute 
symptomatic maternal infection, ZIKV and rubella can be detected in serum, blood, oral fluid or 
urine by PCR amplification of nucleic acid and may precede the development of IgM antibodies. 
Acute primary maternal HSV can be diagnosed by viral PCR and the presence of IgM antibodies 
but usually only when oral or genital lesions are present. Virus may be detected for up 10 weeks 
in serum following acute ZIKV29 and two weeks following acute rubella91 while CMV and HSV 
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are frequently shed asymptomatically from mucosal epithelia.92,93 Detection of T. gondii IgA is 
the most sensitive indicator of congenital infection in the child.94 CMV shedding in oral fluid 
may occur both during primary infection and asymptomatic reactivation and is therefore not 
always a reliable indicator of acute primary infection. Detection of virus needs to be interpreted 
in the light of serological results.66  
 
Serological testing in pregnant women 
For rubella, T. gondii and CMV commercial enzyme immunoassays are routinely available for 
antibody detection. For rubella and toxoplasmosis cases, serological diagnosis of acute primary 
infection relies on detection of acute phase IgM antibodies, which for most do not reach adequate 
levels until one week following acute infection. For all three, paired IgG samples taken at least 
10-14 days apart should also be obtained to confirm seroconversion. A fourfold rise in antibody 
titre is indicative of recent although not necessarily primary infection.94 T. gondii IgM antibodies 
are commonly detected by ELISA in acute infections, but may persist for several months.95 High 
levels of IgG antibodies may also be present during the acute phase of infection.96  
In general, detection of CMV IgM, has been shown to lack sensitivity and specificity, especially 
in conditions of immune dysfunction. A positive CMV IgM is associated with primary infection 
in only 10% of cases. To distinguish between acute and chronic infections, ELISA-based IgG 
avidity tests are widely recommended: low-avidity antibodies are typically found over the first 
weeks, while high-avidity IgG predominates in the chronic phase.93  
IgM and IgG antibody tests for dengue, West Nile fever and ZIKV members of the flaviviridae 
family share considerable epitope cross-reactivity. Plaque reduction neutralising tests can be used 
to differentiate closely related viruses but is too complex for routine diagnosis especially in non-
specialised laboratories.  
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In-utero testing 
In the event that acute maternal infection with any of the above pathogens is considered to pose a 
risk, infection of the infant can be investigated where possible by amplification of pathogen 
nucleic acid from amniotic fluid. Amniotic fluid samples are typically obtained at 18 weeks 
gestation to determine fetal infection with T. gondii and guide therapy.97 In CMV infection, there 
is a 6-8 week window between maternal infection and being able to detect the virus in amniotic 
fluid. PCR has high sensitivity when performed at the correct time (20-21 weeks gestation or 7 
weeks after maternal infection) and, when combined with culture, nearly all congenital infection 
can be diagnosed.63 PCR testing of amniotic fluid for HSV is possible but does not seem to 
correlate with neonatal infection,98 and has recently been shown to be possible with ZIKV.99 
 
Screening  
Childhood immunisation programmes against rubella are routinely available in 147 countries, 
with an estimated global coverage of 46%.100 Pregnant women may be screened for rubella 
antibody and those in whom levels are absent or low, offered post-partum vaccination. Recently, 
high coverage levels of immunisation have led to some high-income countries to drop rubella 
screening. Prenatal screening for toxoplasmosis is routinely undertaken in Austria, France and 
Slovenia and neonatal screening in Denmark, Ireland and some parts of USA and Brazil.95 In 
France, women who develop high titres of IgM antibodies or evidence of seroconversion 
indicative of primary infection during pregnancy are offered fetal screening and treatment with 
spiramycin or pyrimethamine-sulphonamide. Severe sequelae from congenital toxoplasmosis are 
now rarely seen after the current approach of systematic prenatal screening and treatment was 
implemented in France.101 Screening for CMV in some high-income countries and for ZIKV in 
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countries with high levels of transmission are being considered however, it is not currently 
recommended for either. 
 
Clinical presentation at birth 
Whilst infection can cause both primary and secondary microcephaly, the main focus of this 
review is the effect of congenital infections on neurogenesis or antenatal neural progenitor death 
usually associated with primary microcephaly, i.e. it is present at birth. Evaluation of an infant 
with suspected microcephaly at birth seeks to meet three goals: (1) confirm the diagnosis of 
microcephaly; (2) identify the cause and attempt syndromic diagnosis; and (3) aid prognosis and 
guide initial treatment where appropriate.  
Measurement of the OFC (illustrated in Figure 3) is used as a screening examination to identify 
neonates who are likely to have an underlying neurological condition. A full antenatal history 
with particular focus on acquired environmental insults, maternal serology, antenatal fetal growth 
measurements where available, and family history of microcephaly and neurological conditions 
are essential to identify possible causes. Systemic examination, including ophthalmology and 
audiology, will help in identifying associated abnormalities in other organ systems. Cranial 
ultrasound (crUS) can be used to screen for anatomical abnormalities where available. Features 
suggestive of congenital infections in an infant with microcephaly are: maternal history of 
infection during pregnancy, indicative antenatal maternal serology results, clinical features in the 
neonate (Panel) and calcifications on brain imaging. In patients with these features, a more 
specific work-up is required, including serological testing to confirm specific infectious causes, 
other laboratory investigations, and further neuroimaging.  
  
Identifying Specific Infectious Causes 
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Common clinical features for each infection are shown in the appendix and a summary of 
diagnosis and treatment recommendations are given in Table 2. Much of this information is based 
on historical cohorts and case studies and is therefore potentially prone to bias. Individual patients 
may present with different signs and symptoms.  
 
CMV 
Most neonates with congenital CMV are asymptomatic but common manifestations in 
symptomatic neonates include intra-uterine growth restriction, sensorineural hearing loss, 
petechiae, and jaundice. Neurological sequelae are observed in 60-90% of those with clinical 
symptoms at birth,102 although biases from early cohort studies may overestimate this.72,103,104 Up 
to 15% of infants that are asymptomatic at birth may go on to develop symptoms later in 
childhood.63,102,104  
 
HSV 
Infection can occur in utero, intrapartum or postnatally. In utero infection is classically associated 
with a triad of cutaneous, ophthalmological and neurological abnormalities (including 
microcephaly). Vesicular lesions may or may not be present and often develop late. Perinatal 
infection presents in 3 main ways: disseminated disease affecting multiple sites, CNS disease or 
skin/eyes/mouth limited infection.75,105  
 
Rubella 
Fetal abnormalities resulting from in utero transmission of rubella range in severity according to 
the gestation at the time of infection. Infection in the first trimester is associated with more severe 
abnormalities.106 Symptomatic infection in the infant is referred to as congenital rubella syndrome 
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(CRS) with a classic triad of cataracts, sensorineural deafness and cardiac defect (e.g. patent 
ductus arteriosus, ventricular septal defect).107 Estimates of the frequency of microcephaly in 
CRS vary but have been reported to be as high as a third of cases overall.108  
 
T. gondii  
Approximately 24% of live born infants infected with T. gondii are symptomatic at birth.109 The 
classic signs originally described by Sabin (chorioretinitis, microcephaly or hydrocephalus, and 
widespread intracranial calcifications) are relatively infrequent, but highly suggestive of the 
diagnosis of congenital toxoplasmosis. More severe manifestations occur in infections earlier in 
gestation. Intracranial lesions, for example, are seen in up to 40% of congenital infections 
acquired before 5 weeks of pregnancy but in less than 10% of those acquired beyond 20 weeks.109 
12·5% of liveborn infants with congenital toxoplasmosis develop severe neurological sequelae;110 
5% of them have microcephaly.111  
 
ZIKV 
ZIKV infection in pregnancy and its possible link to a range of birth defects is currently the 
subject of intense investigation worldwide. There is now convincing evidence that ZIKV 
infection in pregnancy, especially in the first trimester, is associated with an increased risk of 
microcephaly. The risk of microcephaly associated with ZIKV infection was estimated as 95 per 
10,000 infected women in first trimester in French Polynesia.112 Congenital disease has 
predominantly been seen in Brazil, but this may spread across Latin America. Brasil et al 
followed up ZIKV affected pregnant women in Rio de Janeiro and found that 3.4% had 
microcephaly and 42% had abnormal clinical or radiological findings in the first month, mostly 
affecting the central nervous system.113 The spectrum of congenital Zika syndrome (CZS) 
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includes birth defects associated with microcephaly (including hearing loss and ophthalmological 
defects) and how they are related to timing of infection, and presence or absence of maternal 
symptoms, as well as the influence of other arboviral infections has yet to be fully delineated. 
Currently, most of what is known about CZS comes from neonates with microcephaly which 
appears to include syndrome-specific features such as partially collapsed skull, reduced cortical 
thickness and extensive subcortical calcifications.114,115 However, the full spectrum will only 
become clear when cohorts of infected mothers provide in-depth report of the clinical 
presentation. Brain damage or ocular lesions can be found in the absence of microcephaly and 
other features, as described in the appendix, are common.14,116,117  It is yet to be shown whether 
there is ongoing viral replication at the time of birth in congenital ZIKV infection. This will have 
important implications for the potential efficacy of postnatally administered antiviral therapy.  
 
Markers for Prognosis  
Microcephaly outcomes are varied, and more accurate prognosis at the time of diagnosis is one of 
the main aims of clinical evaluation of the neonate. Neuroimaging- for example crUS, CT and 
MRI-  has proven a useful predictive investigation and is warranted in neonates with severe 
microcephaly, or where a congenital infection is suspected.118 Whilst different modalities have 
specific advantages (e.g. good visibility of calcifications on CT, bedside availability of crUS), 
many structural abnormalities caused by disruptions in development can be identified across 
modalities. Typical abnormalities include intracranial calcifications, white matter abnormalities 
(e.g. periventricular leukomalacia, delayed myelination; best seen on MRI), gyration defects (e.g. 
polymicrogyria), and schizencephaly.12,119   
 
Long-term consequences and resulting disability in childhood  
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Long-term follow-up is recommended for infants with microcephaly and even for those with 
congenital infections and who are apparently unaffected at birth in order to manage evolving 
conditions and identify new manifestations early. In many cases, the cause of microcephaly will 
not be known and generic plans can be adopted to manage impairments and limit disability. The 
timing of the interventions vary in importance. Hearing screening for example needs to be done 
early to enable interventions to optimise language development. Other interventions, including 
psychosocial support and counselling,120 are required throughout childhood and into adult life.   
Where microcephaly occurs, recommendations are for early intervention to address associated 
impairments, calling upon a host of specialist medical and educational services.121 Currently, 
regular follow-up is recommended for ZIKV associated microcephaly for anthropometry, 
developmental and neurological assessments and also hearing and ophthalmological assessment 
where required over the first two years, with less frequent follow-up recommended for infants 
without microcephaly.1 Evidence-based therapy strategies exist that may improve cognitive 
outcomes and reduce disability.122 Interventions in early life, for example child stimulation,123 
maximise the plasticity of the developing brain, attenuating the consequences of the damage to 
the nervous system. But such recommendations ignore the realities of life in many countries. 
Issues begin at birth, for example, in some societies, children with visible disabilities are allowed 
to die in the neonatal period, either through active infanticide or through withdrawal of basic care 
such as feeding.124  
The provision of both recommended early diagnosis, and appropriate interventions may be 
severely limited in countries with only a handful of specialists, where early intervention 
programmes or inclusive education efforts remain rare and are largely urban-based. Based on a 
small but growing literature on disability, individuals with more severe disabilities are far less 
likely to receive appropriate medical care, attend school or are included in the social, economic or 
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religious life of their communities.125 This is compounded in poorer households, which often 
choose to invest limited resources on non-disabled children, whom they feel will be able to 
contribute to the household in future.126 Furthermore, recommendations for individuals with 
microcephaly tend to concentrate on early childhood, but anticipate little about their management, 
support or advocacy needs beyond pre-school years. While attitudes vary from society to society, 
overwhelmingly, persons with disabilities face increased risk of stigma, social isolation, abuse 
and poverty across their lifespan.127 
Infections that cause microcephaly are likely to disproportionately affect LMICs and within these 
countries, the poorest populations, who are more likely to live in crowded areas with inadequate 
housing and limited water and sanitation systems. Compounding this, poorer women are less 
likely to have access to family planning services, to access prenatal screening or, if needed, safe 
termination of pregnancy.128 
Although social protection schemes are beginning in many middle-income countries,129 the cost 
of raising and supporting a disabled child continues to be borne almost entirely by the immediate 
family. Households with disabled members are on average, poorer because of increased costs and 
because family members, in particular women, must take time away from income generating 
activities to provide care.130  
Improved services and support for affected individuals and families across the lifespan must be 
anticipated, and health professionals must work with civil society organisations, including 
disabled peoples organisations, to ensure these children and their families receive the medical, 
educational and social service support they need and are entitled to.131 
 
Conclusions 
We have summarised the epidemiology, clinical presentation and the current understanding of the 
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pathogenesis of the major congenital infections associated with microcephaly. Potential 
inconsistencies in the criteria used to diagnose microcephaly have been highlighted as well as 
limitations of current diagnostic methods in confirming an infectious aetiology. If microcephaly, 
as strictly defined by head circumference, is used as a screening tool, it will miss affected infants 
who do not manifest with a small head size. Many infants are likely to have subtle deficits 
needing more sensitive neurological and developmental assessments. Microcephaly is also 
usually only one manifestation in a syndrome and other assessments are required to identify the 
full spectrum of illness.  
ZIKV has brought the attention of the world to the problem of microcephaly. The extent of the 
disease burden resulting from ZIKV is still being clarified but it appears to be significant and is 
one of a number of infections associated with primary microcephaly. On an individual level, 
accurate diagnosis and thorough investigation of confirmed microcephaly can guide management 
and determine prognosis. On a population level, assessing the overall burden and contribution of 
different causes will guide future interventions and strategies for prevention. Preventing infection, 
where possible, must be prioritized. It is not within the scope of this review to fully consider 
health protection and primary prevention but key interventions exist, for example population 
immunisation for rubella and vector control for ZIKV. Pharmacological interventions are able to 
treat some congenital infections and therefore limit further damage to the child’s developing 
nervous system (CMV, HSV, T.gondii). Antiviral treatments are not currently available to treat 
ZIKV in pregnancy but vaccines are in development. Interventions to attenuate the effects of the 
developmental delay, and at the community or population level to minimize impairment caused 
by infections that can lead to microcephaly are all needed. More clinical and health system 
research is crucial to provide scalable interventions to reduce the disability associated with 
microcephaly. Many interventions designed to optimise neurodevelopmental outcomes in 
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infected infants will be common to all congenital infections and enhanced services for ZIKV 
follow up could potentially also be used in the future for the benefit of children severely affected 
by other congenital infections. 
Regions in which the infective burden is highest are also likely to be those where diagnosis and 
management is most lacking, creating a disproportionately large burden on populations that can 
least afford it. Inequities in access to optimised multidisciplinary care for children with 
neurodisability in areas with the highest rates of microcephaly means that the prognosis for those 
infants is often very poor. ZIKV has highlighted the issue of microcephaly and provides a timely 
opportunity to refocus on the whole group of infectious diseases which can affect the developing 
fetal brain and to redouble our efforts for prevention and treatment in the short- and long-term for 
those living with the frequently devastating consequences of such congenital infections. 
 
 
Panel: Clinical features suggestive of congenital infection in a neonate with 
microcephaly.132,133 
 Severe microcephaly (<-3 z-scores) 
 intrauterine growth restriction 
 hydrops fetalis 
 seizures  
 cataract and other visual abnormalities  
 hearing loss 
 congenital heart disease 
 hepatosplenomegaly 
 jaundice 
 characteristic rashes  
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Table 1. Summary of the microbiological, virological and maternal clinical features 
Organism Description Transmission Risk period for 
transmission of infection 
to the fetus 
Maternal signs and 
symptoms 
Prevention of infection and 
treatment of pregnant 
women  
CMV Betaherpes DNA 
virus 
Herpesviridae 
family 
Infectious body fluid (saliva, 
urine, breast milk, genital 
secretions, blood transfusion). 
Risk increases with 
gestational age, but earlier 
infection is associated with 
more severe congenital 
infection. 
Mostly asymptomatic or 
flu-like symptoms 
Treatment with antiviral 
medication not currently 
recommended outside of 
trial settings.  
Candidate vaccines are in 
development. Hyperimmune 
globulin has been trialled but 
has not as yet been shown to 
reduce transmission of CMV 
to the fetus.134  
HSV 1 & 2 Alphaherpes 
DNA viruses. 
Herpesviridae 
family 
Orogenital, genital-genital, 
transmitted during delivery 
through infected maternal 
genital tract. 
Virus shed with or without 
Risk is associated 
predominantly with 
primary infection late in 
pregnancy.  
Primary genital herpes 
infection may be 
asymptomatic but is often 
associated with 
mucocutaneous lesions.75 
Risk of perinatal 
transmission can be reduced 
by Caesarean section in the 
context of active genital 
lesions and suppressive 
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lesions present. Latent infection is 
subsequently established in 
dorsal root ganglia. 
Mucocutaneous lesions can 
then recur following viral 
reactivation.105 
aciclovir/valaciclovir given 
to the mother prior to 
delivery.135 
 
Rubella virus Single stranded 
RNA virus 
Togaviridae 
family 
Respiratory transmission. 
Humans are the only known 
host of rubella.136   
Risk of congenital disease 
in first 20 weeks; infection 
beyond this not associated 
with congenital defects. 
Primary maternal infection 
is associated with up to a 
50% risk of fetal 
infection.137 
Typically a mild self-
limiting illness 
Maculopapular rash, 
lymphadenopathy, malaise, 
arthralgia, fever.136   
Immunisation of girls to 
prevent individual cases and 
the whole population to 
interrupt transmission.  
Supportive management of 
the infection. 
T. gondii Obligate 
intracellular 
protozoan 
parasite 
 
Humans acquire infection 
mainly by consuming raw or 
undercooked meat containing 
cysts, by ingesting water or 
raw vegetables contaminated 
with oocysts, or by 
Risk of congenital 
transmission increases with 
gestational age at maternal 
infection: 15% (95% CI 
13–17) at 13 weeks and 
71% (95% CI 66-76) at 36 
Most acute T. gondii 
infections in 
immunocompetent 
pregnant women are 
subclinical; fever, 
lymphadenopathy and a 
Treatment with spiramycin 
and/or pyrimethamine-
sulphonamide of maternal 
toxoplasmosis diagnosed 
through prenatal screening is 
believed to reduce the risk of 
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transplacental transfer of 
tachyzoites during an acute 
infection. Tachyzoites invade 
host cells, multiply and 
disseminate, infecting 
multiple sites in the body 
including brain, eye, heart, 
skeletal muscle and 
placenta.138  
Toxoplasmosis reactivation in 
immunocompromised women 
may rarely be a cause. Blood 
transfusion or organ 
transplantation. 
The only definitive hosts are 
members of the cat family.138  
weeks.109 flu-like illness are the most 
common clinical signs and 
symptoms.138 
mother-to-child transmission 
and neurologic sequelae in 
the fetus in settings where 
low-virulence type II strains 
predominate, but this 
protective effect remains to 
be confirmed against more 
virulent atypical 
recombinant strains.101  
ZIKV 
(much 
knowledge 
still 
Single stranded 
RNA arbovirus 
Flaviridae 
The main vector is the Aedes 
mosquito. A. aegypti is 
considered of greatest global 
importance.139  
Risk of transmission 
appears to be throughout 
pregnancy 
Infection is often 
asymptomatic in adults 
with symptoms reported in 
approximately 20% of 
Primary prevention of 
mosquito bites. No treatment 
as yet.  
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provisional)  family 
 
There are 
currently two 
major lineages: 
one African 
(with two 
groups, the 
Uganda cluster 
and the Nigeria 
cluster) and one 
Asian/American.  
 
Also sexual transmission and 
potentially through infected 
blood transfusion.140   
Non-human hosts are thought 
mainly to include non-human 
primates, although evidence 
of infection has also been 
demonstrated in other 
mammals.139 
  
 
 
cases.141  
Common features include 
pruritic, maculopapular 
rash, low grade fever, 
arthritis/arthralgia, 
conjunctivitis, myalgia and 
headache.  
Has been associated with 
Guillain-Barré syndrome, 
myelitis and 
meningoencephalitis 
reported in adults.142  
Table 2: Diagnosis and treatment of infants 
Organism Diagnosis Treatment 
CMV CMV viral culture or PCR testing for DNA from urine or saliva 
obtained within the first three weeks of life. Retrospective diagnosis 
can be achieved from dried blood samples taken for newborn 
screening. Testing should be done as early as possible. 
Early treatment of confirmed symptomatic congenital CMV with IV 
ganciclovir or oral valganciclovir is currently recommended based 
on the results of 2 main trials.143-145 Results from randomised trials 
and observational studies have demonstrated improved hearing and 
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neurodevelopmental outcomes although questions remain regarding 
optimal treatment strategies, including when to treat and duration of 
therapy. 
HSV 1 & 2 PCR testing for viral DNA on surface swabs (conjunctivae, mucosal 
surfaces), cutaneous lesions, CSF, whole blood, and tracheal 
secretions where available. 
Intravenous high-dose acyclovir is indicated for confirmed neonatal 
HSV infections.146  
 
Rubella Isolation of rubella virus (or viral RNA) from the neonate, isolation 
of rubella IgM or persistent rubella IgG. The virus is most 
commonly isolated from nasopharyngeal samples, but can be from 
blood, urine, and CSF cultures.147 
Management is mainly supportive and involves monitoring for late 
emerging symptoms (e.g. hearing loss, endocrine problems). 
T. gondii Diagnosis is difficult if specific IgM and IgA antibodies are not 
detected in the serum or plasma at birth. CSF samples to detect IgM 
and IgA antibodies may confirm the diagnosis in infants with 
intracerebral lesions. 
Maternal IgG is detectable in the fetus for several months, generally 
disappearing completely within one year. Because specific IgG 
produced by congenitally infected newborns may be detected about 
12 weeks after birth, the presence of high IgG titres beyond this time 
is suggestive of congenital infection.95 
Congenital toxoplasmosis is treated with pyrimethamine and 
sulphonamide (sulphadiazine or sulphadoxine) with folinic acid to 
minimize pyrimethamine-associated hematologic toxicity. Up to 
85% of children with subclinical congenital infection, if left 
untreated, will later develop signs and symptoms of disease, such as 
chorioretinitis or developmental delays.148 
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ZIKV 
 
Testing for IgM antibody with capture ELISA using recombinant 
antigens in CSF or blood at birth indicate congenital infection; 
plaque reduction neutralisation tests are required to confirm 
monotypic antibody responses, although dengue and yellow fever do 
not cause congenital infections. Reverse-transcriptase PCR detects 
acute infections, positivity rare in neonates. Tests can be done on 
serum/plasma from cord blood or infant's peripheral blood. IgM 
detection in CSF of neonate is highly specific. 
Clinical management of complications, including dysphagia, 
irritability and epilepsy. Supportive care for neurocognitive delays, 
hearing and visual loss, and appropriate developmental follow-up. 
CNS = central nervous system, CSF = cerebrospinal fluid, PCR = polymerase chain reaction 
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Figure 1: Modelled population effects of insults to brain developmental  
* Bars represent the OFC distribution at birth (z-scores on x axis). The dark bar segments indicate 
the head circumference measurements of these “affected” children. The continuous line 
represents the reference population (no children “affected”), with a mean of 0 and SD of 1. 
Simulated populations were created using R language and environment for statistical 
computing.149 
If an otherwise normal population of 1000 infants (in which children's occipito-frontal 
circumferences (OFCs) are close to their expected values) is exposed to a congenital infection 
that limits brain development, a proportion of children are labelled as “normal” by being above 
the -2 z-scores (standard deviations (SD)) or -3 z-scores cut-offs but they may deviate from their 
“expected” OFC.  
Scenario 1 describes a congenital infection with a uniform shift to the left by 1 SD relative to the 
reference curve in 30% (randomly chosen) of affected children, roughly as expected in congenital 
toxoplasmosis acquired late in pregnancy. The remaining 70% children were not affected at all. 
In this hypothetical scenario, 6·5% of children fall below -2 z-score cut-off value for 
microcephaly; 0·9% below the -3 z-scores. Only 65 of the 300 (21·7%) of the “affected” children 
will actually be classified as “microcephalic” by using the -2 z-score cut-off. Only children whose 
“ideal” OFC would be less than -1 SD of the expected mean (expected proportion of 15·9% in a 
Scenario 1 Scenario 1
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healthy population), would actually be diagnosed as “microcephalic” after the 1 SD shift caused 
by the infection.  
Scenario 2 is a congenital infection where OFC is shifted to the left by 2 SD in 10% of children, 
roughly as expected for congenital toxoplasmosis acquired early in pregnancy. In this 
hypothetical scenario, 6·5% of children fall below -2 z-score cut-off value for microcephaly; 
1·4% below the -3 z-scores. Here, 65% of “affected” children will fall below the cut-off value of 
-2 SD.  
By counting the number of children below a given cut-off value we are severely underestimating 
not only the proportion of children who have been relatively mildly affected (Scenario 1) but also 
that of children who have been more severely affected (Scenario 2). Moreover, although 
Scenarios 1 and 2 represent conditions varying in severity which affect different proportions of 
children in the population, in both examples the prevalence of microcephaly, estimated by 
applying the -2 z-score cut-off, would be quite similar (around 6.5%).  
 30 
 
Figure 2. Factors that may influence neuronal and neural progenitor populations and lead 
to microcephaly or macrocephaly 
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Figure 3: Measurement of occipito-frontal circumference (OFC) in the neonate  
Measurements of OFC can be variable and user dependent. To aid robust measurements, a non-
stretchable tape should be used and placed above the ears, covering the broadest part of the 
forehead, and the most prominent area of the occiput as shown. The largest measured 
circumference of three repeat measures should be used and recorded to the nearest millimeter. In 
neonates, the most robust measurements are achieved at >24h of age when post-partum skull 
modelling has subsided. 
 
 
Search strategy 
Pubmed, Embase and Google Scholar were searched, with no language or date restrictions 
(search end date: 31 March 2017), for the following terms and reference lists were searched for 
additional citations: 
 (Cytomegalovirus or CMV or Rubella or MMR or Zika or HSV or herpes or toxoplasma or 
toxoplasmosis) and (seroprevalence or prevalence or incidence) 
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 (congenital pathogenic infections or pathogenic infections) and (brain disorders or microcephaly) 
 (pathogens or virus or pathogen or viral) and microcephaly  
 (Cytomegalovirus or CMV or Rubella or MMR or Zika or HSV or herpes or toxoplasma or 
toxoplasmosis) and (brain or brain disorder or brain development or brain defects) 
 (cytomegalovirus or rubella or toxoplasmosis or herpes simplex or varicella or chikungunya or 
West Nile virus or HIV or syphilis) AND microcephaly NOT Zika 
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